The phrase "additional strength of the study" is correct and usable in written English.
It can be used when discussing the positive aspects or contributions of a research study in a report or academic paper.
Example: "One additional strength of the study is its large sample size, which enhances the reliability of the findings."
Alternatives: "further advantage of the study" or "extra merit of the study".
An additional strength of the study is a control group programme.
An additional strength of the study is the involvement of patients in the design of the survey questionnaire.
An additional strength of the study was the good agreement between maternal and subject reporting of adolescent body size.
We will be monitoring the reliability and validity of the intervention which is an additional strength of the study.
An additional strength of the study design is that we evaluated patients without hypertriglyceridemia, and patients without treatments that may influence HDL levels.
An additional strength of the study was the availability of a matched comparator group of obese patients who did not undergo surgical weight loss intervention.
The relatively large sample size and the use of primarily standardized measures represent additional strengths of the study.
Additional strengths of the study are the generalisability to pre-frail older people and aged care health service settings, and the robust, but pragmatic, clinical trial design.
Additional strengths of the study include the large sample size, recruitment through cases identified from the national cancer registry, availability of detailed risk factor information, as well as multiple EBV serological markers.
The detailed risk factor information concerning indoor air pollution and family history collected from patients following diagnosis, as well as similar participation rates among cases and controls are additional strengths of the study.
An additional strength of the AFFIRM study was its placebo-controlled design, because, at the time the study was designed, there was no approved second-line therapy following progression on docetaxel-based chemotherapy for patients with castration-resistant prostate cancer.
